Hematology malignancy is often complicated by many critical diseases including DIC. The resolution of DIC safely is one of the most important aspects in getting over hematological malignancy. We would like to report our comparative review of the administration of Recombinant Thrombomodulin (Recomodulin) versus Dalteparin Na (Fragmin) and this time, we would also report the possibility of reducing blood products such as fresh frozen plasma (FFP).Patient
Thirteen patients (mean age 57.0 years, men/women 5/8, AML 7, APL 4, ALL 2) were administered recombinant thrombomodulin and 13 patients (mean age 50.5 years, men/women 8/5, AML 6, APL 4, ALL 3) were administered Dalteparin Na.Result
The mean duration of therapies was 3.8 and 11.3 days, respectively. All patients has achieved DIC resolution, and the mean resolution time was 5.5 and 11.6 days (P = 0.020). The mean administration of FFP was 7.5 and 16.9 units (P = 0.091). The average of FDP, Fib, and JMHW DIC score has improved in both therapies. On the other hand, there were no changes in PT-INR and AT3. No bleeding and other adverse events were reported during both administration.Conclusion
Recombinant thrombomodulin adminisitration is effective therapy rather than Dalteparin Na administration for patients with hematological malignancy and also tends to reduce the use of FFP.